Oncolytics Biotech, Inc.

Twitter LinkedIn
  • Home
  • About
    • Our Company
    • Management Team
    • Board of Directors
  • Technology
    • What is Pelareorep?
    • What Does Pelareorep Do?
    • Delivery
    • Intellectual Property
    • Posters & Publications
    • Manufacturing
  • Clinical Trials
    • Clinical Development Plan
    • Collaborators
    • Pipeline
  • Media
    • Press Releases
    • Insights
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
    • Filings & Financials
    • Corporate Governance
    • FAQs
    • Email Alerts
    • IR Contacts
  • Contact
  • Careers

News

Media

Media

  • Press Releases
  • Insights
Nov 1, 2007

Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference

Oct 30, 2007

Oncolytics Biotech Inc. Announces 2007 Third Quarter Results

Oct 24, 2007

Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial

Oct 23, 2007

Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide

Oct 4, 2007

Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007

Oct 3, 2007

Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe

Sep 28, 2007

Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial

Sep 19, 2007

Oncolytics Biotech Inc. to Present at 8th PEACe Conference on Protein Expression in Animal Cells

Sep 12, 2007

Reovirus Infection of Melanoma Cells Generates Anti-Tumour Immunity

Sep 4, 2007

Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent

    • 1...
    • 49
    • 50
    • 51
    • 52
    • 53
    • 54
    • 55
    • 56
    • 57
    • 58
    © 2022 Oncolytics Biotech, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap